Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characte...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-08-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/7-1360/v1 |
id |
doaj-e4631352a72b4ef786c7073915bfaa49 |
---|---|
record_format |
Article |
spelling |
doaj-e4631352a72b4ef786c7073915bfaa492020-11-25T03:51:01ZengF1000 Research LtdF1000Research2046-14022018-08-01710.12688/f1000research.14474.115758Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]Jun Yamagami0Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, JapanPemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.https://f1000research.com/articles/7-1360/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jun Yamagami |
spellingShingle |
Jun Yamagami Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] F1000Research |
author_facet |
Jun Yamagami |
author_sort |
Jun Yamagami |
title |
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
title_short |
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
title_full |
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
title_fullStr |
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
title_full_unstemmed |
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
title_sort |
recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2018-08-01 |
description |
Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments. |
url |
https://f1000research.com/articles/7-1360/v1 |
work_keys_str_mv |
AT junyamagami recentadvancesintheunderstandingandtreatmentofpemphigusandpemphigoidversion1referees2approved |
_version_ |
1724489228050497536 |